Healthcare Royalty, Inc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Healthcare Royalty, Inc | HCRX - NASDAQ |
Postponed | $0.00 | $0.00 | Postponed | 8/6/2021 |
| Goldman Sachs, Citigroup, Credit Suisse, Jefferies, Cowen, SVB Leerink | ||||||
Co-Manager(s): Truist Securities, BMO Capital Markets, Stifel, Raymond James, Siebert Williams Shank, Cabrera Capital Markets, Drexel Hamilton | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-07-01 Terms Added 2021-07-29 | ||||||
About Healthcare Royalty, Inc (adapted from Healthcare Royalty, Inc prospectus):
They are the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "HCRX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.